Empowering Egyptian Pharmaceutical Manufacturers with cGMP Active Pharmaceutical Ingredients, High-Purity Therapeutic Peptides & Comprehensive Regulatory Dossiers
Send Inquiry NowPrioritized Active Pharmaceutical Ingredients Engine-Calibrated for Egyptian Hospital Systems and Formulators
Understanding Regulatory Transformations, Vision 2030 Localization Directives, and Supply Chain Architecture
The Arab Republic of Egypt stands as the largest pharmaceutical producer and consumer market across the Middle East and North Africa (MENA) region. Valued at over USD 4.5 billion annually, the Egyptian domestic formulation sector is undergoing a profound structural shift driven by the national strategy, Egypt Vision 2030. With the establishment of landmark infrastructure initiatives such as Gypto Pharma (Medicine City in Khanka), the Egyptian government aims to transition the country from an import-reliant drug recipient into a self-sustaining regional hub for generic pharmaceuticals, oncology therapeutics, and advanced biologicals.
However, despite local formulation capacity covering approximately 92% of domestic finished dosage form (FDF) volumes, Egypt remains critically reliant on international supply chains for over 85% to 90% of its Active Pharmaceutical Ingredients (APIs) and therapeutic raw peptide building blocks. Recent global currency realignments and foreign exchange dynamics have further intensified the imperative for Egyptian drug manufacturers—such as EIPICO, Pharco Pharmaceuticals, SEDICO, and EVA Pharma—to establish direct, resilient, and cost-optimized procurement channels with primary API synth-factories in China.
Navigating API imports into Egypt requires strict compliance with the Egyptian Drug Authority (EDA) regulations (formerly Nodecar/CAPA). The EDA has instituted updated Common Technical Document (CTD / eCTD) filing guidelines, demanding meticulous verification of API synthetic routes, impurity profiles (in accordance with ICH Q3A/B guidelines), residual solvent limits (ICH Q3C), and elemental impurities (ICH Q3D).
A critical localization parameter for Egypt is stability testing compliance under ICH Climate Zone IVb conditions (30°C ± 2°C / 75% RH ± 5% RH). Because of Egypt's arid and high-ambient-temperature geography, APIs exported to Egyptian manufacturers must be backed by real-time and accelerated stability datasets demonstrating physical, chemical, and microbiological integrity under Zone IVb parameters. Gentolex Group provides complete regulatory support packages including Active Substance Master Files (ASMF / DMF), Certificate of Suitability (CEP) documentation, Certificate of Analysis (CoA) per batch, and full CTD Module 3 dossiers formatted specifically for EDA rapid submission and approval.
High-Purity Metabolic, Endocrinological, and Specialty Peptide Intermediates Supporting Local Formulation
Solving Procurement Friction, Customs Bottlenecks, and Formulation Technicalities
Our specialized regulatory taskforce compiles turnkey CTD Module 3 dossiers, provides stability documentation under ICH Zone IVb, and assists Egyptian pharmaceutical companies through fast-track clearance via the Egyptian Drug Authority (EDA).
Optimized logistics routes to Ain Sokhna Port, Alexandria Port, and Cairo International Airport. Complete temperature-monitored cold-chain shipping (-20°C / 2-8°C) for heat-sensitive peptide APIs ensures zero activity loss during transit.
Structured procurement frameworks designed for Egyptian foreign exchange regulations. We work closely with Egyptian banking institutions to facilitate Letters of Credit (L/C), CAD terms, and tailored batch delivery schedules.
Leveraging 250,000 m² of Standardized cGMP Infrastructure for Cost-Effective, High-Yield Production
In the pharmaceutical manufacturing realm, active pharmaceutical ingredients demand uncompromising precision. Gentolex Group operates a state-of-the-art manufacturing campus spanning over 250,000 square meters built to international cGMP, US-FDA, and EU-GMP compliance standards. Our automated synthesis suites utilize digital twin process monitoring, continuous-flow reaction technology, and advanced industrial HPLC purification columns capable of producing kilogram-to-ton scale batches with purity levels consistently reaching ≥99.5%.
By integrating automated peptide synthesizers with real-time analytical process technology (PAT), Gentolex eliminates batch-to-batch variance. For Egyptian pharmaceutical manufacturers, this translates to maximum formulation yield, minimal out-of-specification (OOS) risk during tableting or sterile vial filling, and guaranteed supply continuity—even amid global market volatility.
Utilizing high-efficiency liquid-phase and solid-phase peptide synthesis (SPPS), continuous flow micro-reactors, and automated industrial preparative HPLC systems. We guarantee ultra-low endotoxin levels (<0.01 EU/mg) specifically engineered for injectable finished dosage forms.
Every API shipment bound for Egypt undergoes exhaustive quality control including HPLC purity profiling, LC-MS identity confirmation, GC residual solvent analysis, FT-IR identification, heavy metal screening, and microbiological testing with certified CoAs.
Delivering Integrated Value from Raw Material Synthesis to Finished Dosage Form (FDF) Technology Transfer
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions for Egyptian buyers.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Specialized custom synthesis from milligram research scale to multi-kilogram commercial scale for therapeutic peptides, protected amino acid blocks (Fmoc/Boc), and customized novel sequence setups.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources and FDF licensing out options.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
By pairing world-class chemistry talent with smart automated manufacturing infrastructure, we ensure that pharmaceutical companies in Egypt and across the global market receive robust quality, transparent pricing, and direct technical backing from factory engineers.
Next-Generation Peptide Therapeutics, Green Chemistry & AI-Driven Synthesis for Egypt
As the global and Egyptian pharmaceutical landscape evolves, the demand for complex synthetic peptides and high-potency active pharmaceutical ingredients (HPAPIs) is experiencing exponential growth. Driven by the expansion of therapeutic categories such as metabolic disorders (GLP-1 receptor agonists), oncology, and rare peptide-based drug entities, Gentolex Group has mapped out a strategic technical roadmap through 2030 to empower our Egyptian partner manufacturers.
Transitioning traditional organic solvent synthesis to eco-friendly enzymatic coupling processes. This reduces hazardous waste by over 40% while delivering higher stereospecific purity for complex peptides like Semaglutide and Tirzepatide precursors.
Integrating machine-learning algorithm models into our 250,000 m² production lines to monitor crystal nucleation, peptide coupling kinetics, and impurity generation in real-time, driving batch purity toward 99.8% precision.
Facilitating direct technology transfer and license-out (FDF) packages to Egyptian manufacturing hubs, allowing local formulations to be packaged directly within Egypt under EDA local registration decrees.
In-Depth Insights into Scientific Peptide Manufacturing and Global Regulatory Standards
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of endogenous peptides...
Read Technical Article
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and commercial drug developers...
Read Technical Article
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation...
Read Technical Article
With continuous development in neuroscience and peptide technology, neuroactive peptides have become a pivotal focus area. Semax, derived from an ACTH fragment, features unique sequence kinetics for advanced study...
Read Technical Article
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, supporting bioenergetics...
Read Technical ArticleNeed specialized custom amino acid derivatives or bespoke synthesis for the Egyptian healthcare sector? Gentolex delivers tailored chemical research and commercial manufacturing setup.
Inquire Custom APICommercial, Regulatory, and Technical Guidance for Procurement Directors in Egypt
Accelerate your EDA registration timelines, lower active raw material procurement costs, and secure cGMP API supply lines today. Our technical engineers and regulatory experts are ready to assist.
Send Inquiry Now
